TARDBP and frontotemporal dementia: The development of TDP-43-specific biomarkers is important as it may inform about TDP-43 pathology among clinical subtypes of FTD or AD cases, and could therefore enable the stratification of patients by TDP-43 pathology and eventually result in more precise treatment strategies and better interpretations of clinical trial results.